• SELLAS Life Sciences Group, Inc. reported second-quarter 2026 results, with net loss rising to US$9.61 million from US$6.60 million a year earlier, while basic loss per share from continuing operations narrowed to US$0.05 from US$0.07.
• For the first half of 2026, the company’s net loss increased to US$18.01 million from US$12.41 million, yet basic loss per share improved to US$0.10 from US$0.13, as investor attention was also drawn to renewed interest in immune-based cancer therapies following a landmark Phase 3 cancer vaccine update by larger peers.
• We will now examine how this combination of wider net losses but lower loss per share and rising enthusiasm for cancer vaccines influences SELLAS’ investment narrative.

Outshine the giants: these 16 early-stage AI stocks could fund your retirement.

What Is SELLAS Life Sciences Group's Investment Narrative?

To own SELLAS today, you really have to believe in its immunotherapy platform, especially the GPS cancer vaccine and SLS009, and in management’s ability to turn promising trial data into real, approved products before the cash runs thin. The latest quarter underlined the trade-off: cash burn is widening in absolute terms, even as loss per share improves and the stock has run very hard this year. The broader oncology rally sparked by the Moderna and Merck Phase 3 cancer vaccine update has clearly pulled SELLAS into the spotlight, reinforcing the idea that immune-based approaches could attract more partner and investor interest. At the same time, the company still has no revenue, relies on equity funding, and key readouts like the SLS009 Phase 2 topline data in late 2026 remain binary, near term catalysts. However, there is one funding related risk here that investors should not ignore.

According our valuation report, there's an indication that SELLAS Life Sciences Group's share price might be on the expensive side.

Exploring Other Perspectives

The Simply Wall St Community’s single fair value estimate sits at US$32.50, while recent gains and widening losses, alongside the shifting sentiment around cancer vaccines, show why different investors may reach very different conclusions and why it can help to compare several viewpoints before deciding how this story fits your portfolio.

Explore another fair value estimate on SELLAS Life Sciences Group - why the stock might be worth just $32.50!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your SELLAS Life Sciences Group research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.
• Our free SELLAS Life Sciences Group research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate SELLAS Life Sciences Group's overall financial health at a glance.

Want Some Alternatives?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Rare earth metals are the new gold rush. Find out which 28 stocks are leading the charge.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.